Litigation Details for JANSSEN PHARMACEUTICALS, INC. v. MYLAN LABORATORIES LIMITED (D.N.J. 2020)

JANSSEN PHARMACEUTICALS, INC. v. MYLAN LABORATORIES LIMITED (D.N.J. 2020)

Docket		Date Filed	2020-09-23
Court	District Court, D. New Jersey	Date Terminated	2023-05-23
Cause	15:1126 Patent Infringement	Assigned To	Evelyn Padin
Jury Demand	None	Referred To	Leda Dunn Wettre
Patents	10,143,693; 9,439,906
Link to Docket	External link to docket

Details for JANSSEN PHARMACEUTICALS, INC. v. MYLAN LABORATORIES LIMITED (D.N.J. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-03-21	148	Redacted Document	Patent-In-Suit 693 Patent U.S. Patent No. 10,143,693 Asserted Claims…obviousness-type double patenting over claims 1-16 of US Patent No. 9,439,906 (the 906 Patent) in view of Osborne… for obviousness-type double patenting over the 906 Patent (the patent that issued from the 519 Publication… and an earlier patent incorporated by reference in the 693 Patent, the 693 Patent disclosure would…24 (Berger). IV. THE 693 PATENT 19. The 693 Patent “relates to a method for treating	External link to document
2023-03-21	149	Redacted Document	of the patent-in-suit. That is why U.S. Patent No. 10,143,693 (“the ’693 patent”) thwarts … such patents. Examining the actual prosecution history of the patent reveals what the patent truly…JAMA to the patent office when prosecuting the ’693 patent. Without JAMA before the patent examiner, …this patent in the first place. Because when Janssen’s patent was rejected by the patent office…obtained the ’693 patent by telling the patent office that it was nothing like the ’906 patent because the	External link to document
2023-03-21	150	Redacted Document	Patent-In-Suit 693 Patent U.S. Patent No. 10,143,693 Asserted Claims…including Dr. Forrest’s own patents—the structural features in the 693 Patent are entirely adequate to…It is a bedrock principle of patent law that the claims of a patent define the invention to which the…there are “two elements of a simple patent case, construing the patent and determining whether infringement…) 519 Publication PTX-115 United States Patent Application Publication DTX	External link to document
2023-05-15	172	Order	Products”), infringe upon JPN’s U.S. Patent No. 10,143,693 (the “693 Patent”), specifically Claims 5-7 and…Products will induce direct infringement of the 693 Patent. Mylan has failed to demonstrate that the Asserted…Products will induce direct infringement of the 693 Patent; and it is further Case 2:20-cv-13103-EP-LDW Document… 2020 23 May 2023 2:20-cv-13103 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2023-05-23	174	Order of Dismissal	-7 and 9-14 of United States Patent No. 10,143,693 (“the ’693 patent”) and Mylan’s products that are…infringement and validity claims 5-7 and 9-14 of the '693 patent and Mylan's products that are the subject of ANDA…earlier than the date of expiration of the ’693 patent (currently April 5, 2036). 4. In accordance… 2020 23 May 2023 2:20-cv-13103 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-09-19	96		REPRESENTATIVE CLAIMS U.S. Patent 10,143,693 is being asserted in this case. For ease of…may be referred to as “the ’693 Patent.” The ’693 Patent has 29 claims. Nine of those claims… A patent claim satisfies the definiteness requirement if the specification of the patent-in- suit… for indefiniteness in 2014: “a patent to exclude, the patent statute requires that the …claims are patent ineligible. Mylan bears the burden of proving that the claims are patent ineligible	External link to document